The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines

International Journal of Oncology

Volumn 36, Issue 3, 2010, Pages 553-562

  Katayama, Hiroshi ^a,b,c   Murashima, Teruko ^a,b   Saeki, Yoshiko ^b   Nishizawa, Yasuko ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Androgen; Bicalutamide; Cyclin a; FGF 8

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; CYCLIN A; DNA; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; TESTOSTERONE; THYMIDINE; TUMOR MARKER; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; FGF8 PROTEIN, HUMAN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN A; FIBROBLAST GROWTH FACTOR 8; HUMANS; MALE; MICE; NITRILES; PROSTATIC NEOPLASMS; TESTOSTERONE; THYMIDINE; TOSYL COMPOUNDS;

EID: 77149154640     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000529     Document Type: Article

References (33)

1. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, Vicentini C, et al: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 115: 630-640, 2005.
2. Culig Z: Role of the androgen receptor axis in prostate cancer. Urology 62 (Suppl. 5A): S21-S26, 2003.
3. Lee HJ and Chang C: Recent advances in androgen receptor action. Cell Mol Life Sci 60: 1613-1622, 2003.
4. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002.
5. Kooijman R, Himpe E, Potikanond S and Coppens A: Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines. Growth Horm IGF Res 17: 383-391, 2007.
6. Minesita T and Yamaguchi K: An androgen-dependent tumor derived from a hormone-independent spontaneous tumor of a female mouse. Steroids 4: 815-830, 1964.
7. Nakamura N, Nishizawa Y, Noguchi S, Uchida N, Sato B and Matsumoto K: Action mechanisms of physiological doses of androgen or pharmacological doses of estrogen in growth stimulation of Shionogi carcinoma 115 in mice. J Steroid Biochem 27: 459-464, 1987.
8. Yamanishi H, Tanaka A, Miyamoto K, Takeda M, Nishizawa Y, Koga M, et al: An essential role of androgen-induced growth factor in glucocorticoid-dependent autocrine loop in Shionogi carcinoma 115 cells. J Steroid Biochem Mol Biol 52: 49-53, 1995.
9. Gnanapragasam VJ, Robson CN, Neal DE and Leung HY: Regulation of FGF-8 expression by androgen receptor in human prostate cancer. Oncogene 21: 5069-5080, 2002.
10. Ruohola JK, Viitanen TP, Valve EM, Seppänen JA, Loponen NT, Keskitalo JJ, et al: Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 61: 4229-4237, 2001.
11. Diez C, Bertsch G and Simm A: Isolation of full-size mRNA from cells sorted by flow cytometry. J Biochem Biophys Methods 40: 69-80, 1999.
12. Qian X, Kulig E, Jin L and Lloyd RV: Expression of D-type cyclins in normal and neoplastic rat pituitary. Endocrinology 139: 2058-2067, 1998.
13. Fang M-Z, Mar W-C and Cho M-H: Cell cycle was distributed in the MNNG-induced initiation stage during in vitro two-stage transformation of Balb/3T3 cells. Toxicology 163: 175-184, 2001.
14. (WAF1/CIP1) promotor and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 98: 4510-4515, 2001.
15. + T cells during viral infection. J Immunol 166: 795-799, 2001.
16. INK4a promotor in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. Carcinogenesis 21: 1691-1700, 2000.
17. Tanaka A, Miyamoto K, Matsuo H, Matsumoto K and Yoshida H: Human androgen-induced growth factor in prostate and breast cancer cells: its molecular cloning and growth properties. FEBS Lett 363: 226-230, 1995.
18. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, et al: Molecular alterations associated with LNCaP cell progres-sion to androgen independence. Prostate 60: 257-271, 2004.
19. Dobashi Y, Jiang SX, Shoji M, Morinaga S and Kameya T: Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J Pathol 199: 208-220, 2003.
20. Darbre PD and King RJB: Antiandrogen ICI 176334 does not prevent development of androgen insensitivity in S115 mouse mammary tumor cells. J Steroid Biochem 36: 385-389, 1990.
21. Sumitani S, Kasayama S and Sato B: A role for heparan sulfate in androgen-induced deoxiribonucleic acid synthesis of mouse mammary carcinoma (Shionogi carcinoma 115)-derived SC-3 cells. Endocrinology 132: 1199-1206, 1993.
22. Sato B: Can an autocrine loop explain sex-hormone-dependent tumor growth? Oncology 57 (Suppl. 2): S3-S6, 1999.
23. Yam CH, Fung TK and Poon RYC: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326, 2002.
24. Bukholm IRK, Bukholm G and Nesland JM: Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 93: 283-287, 2001.
25. Aaltomaa S, Eskelinen M and Lipponen P: Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 38: 175-182, 1999.
26. Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 17: 2619-2627, 1998.
27. Miyashita Y, Koga M, Kouhara H, Tanaka A, Kishimoto T and Sato B: Facilitation of autonomous phenotype acquisition in androgen-dependent Shionogi carcinoma 115 cells by transfection of androgen-induced growth factor expression vector. Jpn J Cancer Res 85: 1117-1123, 1994.
28. Tomono M, Toyoshima K, Ito M, Amano H and Kiss Z: Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. Arch Biochem Biophys 353: 374-378, 1998.
29. Schultz K, Fanburg BL and Beasley D: Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 290: H2528-H2534, 2006.
30. Goto GH, Katayama H, Tanigaki Y, Fushiki S, Nishizawa Y and Nishizawa Y: Methylcobalamin inhibits fibroblast growth factor-8 stimulated proliferation and induces apoptosis in Shionogi carcinoma cells. Int J Vitam Nutr Res 78: 21-26, 2008.
31. Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K and Cockshott ID: Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Eur Urol 33: 39-53, 1998.
32. Kwabi-Addo B, Ozen M and Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11: 709-724, 2004.
33. Ozen M, Giri D, Ropiquet F, Mansukhani A and Ittmann M: Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93: 1783-1790, 2001.